NEOTHYLLINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEOTHYLLINE is a small-molecule injectable medication approved in 1953 as an NDA product currently sponsored by Teva. The specific indication and mechanism of action are not publicly documented in available records, limiting assessment of its therapeutic role.
LOE Approaching
This legacy product approaching loss of exclusivity with moderate competitive pressure (30%) signals a declining team and focus on generic transition management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers minimal career growth opportunity, with zero linked job openings and a team likely in retrenchment mode. Roles available focus on defending market share, managing generic transition, and maintaining customer relationships in a declining commercial environment.
Brand Manager (Legacy)Sales Representative
Worked on NEOTHYLLINE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.